Cardiopulmonary bypass significantly reduces surfactant activity in children.
Lung injury remains an important problem after cardiopulmonary bypass. The contribution of altered surfactant concentration or activity to pulmonary dysfunction after cardiopulmonary bypass is unclear. Recent evidence indicates that alveolar surfactant exists in specific aggregate forms that differ with respect to density, phospholipid composition, and function. A transition from surface active, higher density, large aggregates of surfactant to lower density, small aggregates that possess reduced surface activity has been demonstrated after experimental lung injury. The purpose of the present study was to examine surfactant aggregate fractions before and after bypass in children. Twelve acyanotic patients, aged 2 to 12 years, underwent intraoperative pulmonary function testing followed by bronchoalveolar lavage before incision and approximately 1 hour after termination of cardiopulmonary bypass. Saturated phosphatidylcholine pool sizes and total protein content of the small- and large-aggregate fractions of bronchoalveolar lavage fluid were determined. One hour after termination of cardiopulmonary bypass, the ratio of saturated phosphatidylcholine in small-aggregate as compared with that in large-aggregate fractions increased (mean +/- standard error) from 0.19 +/- 0.03 to 0.37 +/- 0.07 (p < 0.02), as did the ratio of saturated phosphatidylcholine to protein in the small-aggregate fraction (from 0.04 +/- 0.01 to 0.08 +/- 0.02, p < 0.05). Reductions in forced vital capacity (-19% +/- 5%), inspiratory capacity (-15% +/- 3%), and small airway flow rates (-32% +/- 6%) were also observed after bypass. These changes were accompanied by a fivefold increase in alveolar polymorphonuclear leukocyte content. The present study suggests that cardiopulmonary bypass of moderate duration in relatively healthy children is associated with surfactant changes that are similar in type and magnitude to those observed in experimental lung injury.
McGowan
F X
FX
Department of Anesthesiology/Critical Care Medicine, University of Pittsburgh School of Medicine, Pa.
Ikegami
M
M
del Nido
P J
PJ
Motoyama
E K
EK
Kurland
G
G
Davis
P J
PJ
Siewers
R D
RD
D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007958:Leukocyte Count; D008168:Lung / Q000502:physiology*; D008297:Male; D008448:Maximal Expiratory Flow Rate; D009504:Neutrophils; D010713:Phosphatidylcholines / Q000032:analysis; D011184:Postoperative Period; D011663:Pulmonary Surfactants / Q000378:metabolism*; D014797:Vital Capacity
D010713:Phosphatidylcholines; D011663:Pulmonary Surfactants